| Schedule of Company's reportable segment net revenues and loss |
The Company's reportable segment net revenues and loss for the years ended December 31, 2025 and 2024, consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, |
|
|
|
2025 |
|
|
2024 |
|
Revenue: |
|
|
|
|
|
|
Collaboration revenue |
|
$ |
123,672 |
|
|
$ |
75,622 |
|
Operating expense: |
|
|
|
|
|
|
Research and development: |
|
|
|
|
|
|
External research and development expenses: |
|
|
|
|
|
|
MRT-2359 |
|
|
8,959 |
|
|
|
12,332 |
|
MRT-6160 |
|
|
7,539 |
|
|
|
15,209 |
|
MRT-8102 |
|
|
19,696 |
|
|
|
10,163 |
|
Other development and discovery programs |
|
|
25,198 |
|
|
|
14,432 |
|
Personnel expense |
|
|
46,241 |
|
|
|
39,796 |
|
Overhead and administrative expense |
|
|
33,867 |
|
|
|
29,631 |
|
General and administrative expenses: |
|
|
|
|
|
|
Personnel expense |
|
|
22,975 |
|
|
|
22,153 |
|
Professional services |
|
|
5,740 |
|
|
|
5,091 |
|
Facility costs and other expense |
|
|
7,665 |
|
|
|
7,927 |
|
Interest and other income, net |
|
|
14,485 |
|
|
|
10,982 |
|
Income tax benefit (provision) |
|
|
1,097 |
|
|
|
(2,570 |
) |
Net loss |
|
$ |
(38,626 |
) |
|
$ |
(72,700 |
) |
|